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Abstract 
Background: Infants born at extreme prematurity are at high risk of developmental disability. A
major risk factor for disability is having a low level of thyroid hormone described as
hypothyroxinaemia, which is recognised to be a frequent phenomenon in these infants.
Derangements of critical thyroid function during the sensitive window in prematurity when early
development occurs, may have a range of long term effects for brain development. Further
research in preterm infants using neuroimaging techniques will increase our understanding of the
specificity of the effects of hypothyroxinaemia on the developing foetal brain. This is an explanatory
double blinded randomised controlled trial which is aimed to assess the effect of thyroid hormone
supplementation on brain size, key brain structures, extent of myelination, white matter integrity
and vessel morphology, somatic growth and the hypothalamic-pituitary-adrenal axis.
Methods: The study is a multi-centred double blinded randomised controlled trial of thyroid
hormone supplementation in babies born below 28 weeks' gestation. All infants will receive either
levothyroxine or placebo until 32 weeks corrected gestational age. The primary outcomes will be
width of the sub-arachnoid space measured using cranial ultrasound and head circumference at 36
weeks corrected gestational age. The secondary outcomes will be thyroid hormone
concentrations, the hypothalamic pituitary axis status and auxological data between birth and
expected date of delivery; thyroid gland volume, brain size, volumes of key brain structures, extent
of myelination and brain vessel morphology at expected date of delivery and markers of morbidity
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which include duration of mechanical ventilation and/or oxygen requirement and chronic lung
disease.
Trial registration
Current Controlled Trials ISRCTN89493983
Background
Extremely premature infants are at high risk of disrupted
brain development with consequent acquired damage,
especially to the white matter because of multiple factors
in an adverse environment. Adverse conditions are
thought to include hypoxic ischaemia, free radical injury
i.e. factors related to their premature birth because of low
concentrations of antioxidants, undernutrition and sep-
sis[1]. At untimely extreme premature delivery (24 – 28
weeks of gestation), brain development is at a critical stage
because neuronal migration has only just completed and
synaptogenesis is occurring: therefore the cellular milieu
is critical[2].
Brain magnetic resonance imaging (MRI) studies of survi-
vors of low birth weight who have subtle cognitive abnor-
malities have shown diminished volumes of the caudate
nucleus and hippocampus. Diminished volumes of the
caudate nucleus and hippocampus were associated with
lower IQ, learning disorder and attention deficit[3,4].
Recent brain MRI studies of preterm infants also show
that quantitative cerebral structural abnormalities are
related to the degree of immaturity at birth and are fol-
lowed by abnormal neurodevelopmental outcome[5].
Preterm infants assessed at term show reduced myelina-
tion when compared to infants born at term[5,6]
Only 70% of infants born before 26 weeks' gestation sur-
vive until expected date of delivery[7]. Of the survivors at
least half have significant neurocognitive disabilities[8,9].
Many factors are associated with an increased risk of neu-
rocognitive impairment. Brain growth following birth is a
major determinant of neurocognitive outcome in these
infants and poor brain growth is recognised as a domi-
nant determinant of neurocognitive outcome[10]. Brain
growth at the expected date of delivery in preterm infants
are key predictors of long-term brain growth and intelli-
gence quotient (IQ) score[10]. This implies that postnatal
head growth is a more important determinant of IQ than
intrauterine growth.
Observational studies have found that low thyroid hor-
mone levels in the first few weeks of life in preterm infants
are associated with poor neurodevelopmental outcome.
(see Table 1). These associations persist after adjustment
for confounders and suggest that hypothyroxinemia dur-
ing the critical window period for brain development
which occurs following birth at extreme prematurity has
important effects on neurodevelopment. However, at
present it is unclear whether poor neurodevelopment is
caused by hypothyroxinaemia or whether the hypothy-
roxinaemia is a consequence of other factors that also
cause poor neurodevelopmental outcome and simply an
associated abnormality.
There is prime facie evidence that thyroid hormones
directly contribute to brain development which leads us
to suspect that hypothyroxinaemia among preterm
infants has adverse effects on brain development. Animal
studies have shown that a deficiency of thyroxine results
in impaired neurological pathways during early neuro-
genesis which results in abnormalities of the cytoarchitec-
ture of specific brain structures such as the hippocampus,
temporal and sensorimotor cortex [11-15]. Eayrs and col-
leagues have shown in early studies[16,17] that perinatal
hypothyroidism in rats alter the density and size of neu-
Table 1: Hypothyroxinaemia in preterm infants is linked with poor neurodevelopmental outcome
Study Participants Outcome
Reuss et al [57] 463 infants born below 33 weeks' gestation 4-fold increased risk of disabling cerebral palsy at 2 years of age 
associated with hypothyroxinaemia
Den Ouden et al [58] 563 infants born below 32 weeks' gestation Higher incidence of neurological dysfunction at 5 and 9 years of 
age associated with hypothyroxinaemia
Leviton et al [36] 1414 infants weighing 500 to 1500 g Double the risk of cerebral white matter changes associated with 
hypothyroxinaemia
Paul et al [59] 343 infants weighing less than 1500 grams Increased mortality and incidence of intraventricular haemorrhage 
associated with hypothyroxinaemia
Lucas et al [60] 279 infants born below 36 weeks' gestation Reduction in IQ at 8 years of age associated with low T3
Meijer et al[61] 563 infants born below 32 weeks' gestation and/or 
birthweight less than 1500 g
Negative score on the three milestones of development at 2 years 
of age associated with hypothyroxinaemiaBMC Pediatrics 2008, 8:26 http://www.biomedcentral.com/1471-2431/8/26
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rones and fibre density in specific brain regions and the
orientation of cortical layers. Berbel et al[18,19] also
described effects on spine density of pyramidal neurones
in the cerebral cortex, organisation of callosal connection
and maturation of dendrite connections as a result of
hypothyroidism. Thyroid hormones are also demon-
strated to increase proliferation of cerebellar granule cells
as well as affect apoptosis which is important in suppres-
sion of proliferation and downgrading of these
cells[20,21]. Thyroid hormones are essential for normal
axonal myelination and for normal interhemispheric
commisure development[22,23]. Thyroid hormones are
also important in regulating transcription of specific genes
expressed in the developing brain[24]. This suggests an
important role for thyroid hormone in the complex devel-
oping brain throughout gestation.
While neurocognitive outcome in childhood is the long-
term concern, previous work has demonstrated that the
size of key brain structures at expected date of delivery is a
predictor of subsequent development and is a more
immediate way to evaluate strategies that aim to enhance
brain growth [9,33]. This is because the size of brain struc-
tures reflect the extent of myelination. Myelination is the
process by which nerve fibres are coated with thin layers
of lipid called myelin. Myelin acts as electrical insulation
and increases the efficiency of nerve fibres. In children
with a congenital lack of thyroid hormone (congenital
hypothyroidism) there is a lack of cerebral myelina-
tion[25,26]. Thyroid hormones are therefore a factor in
the regulation of the extent of myelination during gesta-
tion and after birth. Furthermore, TSH receptors have
been found in early human foetal brain and human astro-
cytes in culture, and they are thought to mediate extrathy-
roidal cyclic AMP independent biological effects of TSH
and stimulation of the type 2 deiodinases in astroglial
cells.[27]
At present, there is a paucity of published data concerning
the relationship between thyroid hormone status and
brain development in extreme preterm infants. Previous
work has demonstrated that the size of key brain struc-
tures and brain volume at term is a key predictor of subse-
quent development[2,6,9,28]. Current evidence also
shows that hypothyroxinemia is common in extreme pre-
maturity [29-33]. Derangements of critical thyroid func-
tion during the sensitive window in prematurity when
early development occurs could have a range of long term
effects for brain development.
A randomised controlled trial of levothyroxine supple-
mentation by van Wassanaer [34,35] enrolled 200 infants
under 30 weeks gestation showed no overall effect of lev-
othyroxine supplementation on medium- or long-term
outcomes. However, post hoc subgroup analysis showed
an improved Bayley MDI and PDI at 2 years and 5.5 years
of follow up among infants born below 27 weeks' gesta-
tion and a better motor outcome in those born below 28
weeks' gestation in the treatment arm. Paradoxically, the
reverse was true for those infants born at 29 weeks' gesta-
tion and above which had a worse Bayley MDI and PDI
developmental score. However, the sample size for this
sub-set of infants with gestational age under 27 weeks
who benefited from the intervention was small with 19
infants in the treatment arm and 27 in the placebo arm.
Several reasons may explain this gestation dependent pos-
itive effect of thyroxine in infants born below 28 weeks'
gestation. Firstly, FT4 concentration in the very immature
infants may be too low to ensure normal brain develop-
ment, of which thyroid dependent maturation in the
brain takes place in the window period before 30 weeks.
It is also possible that thyroid hormones are important in
its role of repairing ischaemic damage of the brain which
commonly occurs in extreme prematurity[36].
This study is an explanatory randomised controlled trial
of levothyroxine vs placebo in infants born below 28
weeks' gestation to determine the effects on brain volume,
and development, the hypothalamic-pituitary-adrenal
(HPA) axis and somatic growth (see TIPIT protocol[37]).
This trial will provide the opportunity to assess whether
supplementation with a thyroid hormone during devel-
opment up until 32 weeks gestation affects the extent of
myelination because we are undertaking detailed cranial
MRI in a subset of trial participants. An MRI technique
called Diffusion Tensor Imaging will assess the structural
integrity of the white matter[38,39]. The anisotropy of
water diffusion will be measured which is dependent on
the degree of myelination. In addition, we aim to qualita-
tively and quantitatively evaluate the effect of thyroid hor-
mones on cerebro-vascular morphology, including vessel
size (using measures of diameter), architecture (using
measures of tortuosity) and vessel density in extremely
premature infants and to understand more about the
interdependence of vessel and brain development and
their relationship to prematurity. In addition, this trial
will determine whether the effects of levothyroxine on the
regulation of brain development are clinically relevant.
Important outcomes that will be assessed with cranial
MRI are the extent of white matter myelination and integ-
rity, vessel morphology and the volumes of key brain
structures at term equivalent which will be detailed in this
protocol.
All infants recruited to the TIPIT study[37] will be con-
sented separately to have cranial MRI scans at term equiv-
alent. This protocol describes the study we will perform
on the infants that have cranial MRI scans.BMC Pediatrics 2008, 8:26 http://www.biomedcentral.com/1471-2431/8/26
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Hypothesis
We speculate that a deficiency of thyroxine results in
impaired neurological pathways during early neurogene-
sis which results in abnormalities in myelination and
alters the cytoarchitecture of specific brain structures such
as the hippocampus, caudate nucleus and thalamic
nuclei. The study hypothesis is that supplementation with
levothyroxine is associated with significant differences in
markers of myelination and brain architecture on cranial
MRI.
Objectives
To measure markers of myelination and brain architecture
on cranial MRI among extreme preterm infants (< 28
weeks gestation) recruited to an explanatory randomised
controlled trial[37] to determine the effect of thyroid
replacement therapy on:
￿ whole brain volume
￿ specific brain structures volumes- caudate, hippocam-
pus, thalamus
￿ pituitary height
￿ brain vessel morphology
￿ white matter structural integrity
Methods
Design of TIPIT study
A randomised placebo controlled trial of levothyroxine
postnatally until 32 weeks' corrected gestational age
(CGA) in infants born below 28 weeks' gestation, with
blinding of parents, care providers and outcome assessors.
Infants will be enrolled as soon as possible within five
days of life.
Study population
All infants must fulfill the inclusion criteria.
Inclusion criteria:
a) Infants with gestational age below 28 weeks at birth
b) Recruitment within five days of birth
c) Single or multiple births
Exclusion criteria:
a) Infants born to mother with known thyroid disease or
on antithyroid medications during pregnancy
b) Infants born to mother who are on amiodarone during
pregnancy
c) Infants diagnosed with major congenital or chromo-
somal abnormalities known to affect thyroid function or
brain development
d) Maternal death during or within 5 days after childbirth.
Study Medication
We will use two forms of the active medication: intrave-
nous levothyroxine (tradename: Levothyroid) and oral
levothyroxine solution (tradename: Evotrox) with corre-
sponding placebos during the study period.
In the initial phase, infants will receive either intravenous
Levothyroid or placebo (5% dextrose) within the first 5
days after birth. The treatment regime will follow the dos-
age guidelines determined by previous studies at 8 mcg/kg
birthweight/day single daily dose.
In the next phase, once enteral feeds are fully established,
oral solution Evotrox or placebo (carrier solution without
active drug) will be given at 8 mcg/kg birthweight/day sin-
gle daily dose until the baby reaches 32 weeks CGA.
Overview of assessments
￿ Thyroid hormone levels and the HPA axis will be meas-
ured at baseline, day 14, day 21, day 28 and 36 weeks
(corrected age).
￿ Growth and auxology measurements will be measured
at baseline, day 14, day 21, day 28 and at 36 weeks CGA
￿ Cranial ultrasound and thyroid ultrasound will be meas-
ured at 36 weeks CGA
￿ Magnetic resonance imaging (MRI) and magnetic reso-
nance angiography (MRA) scan at term equivalent
Design of MRI study
MRI and MRA will be performed at a 1.5 Tesla Achieva
Nova MRI scanners (Phillips Medical Systems, Best, Neth-
erlands) at the Royal Liverpool Children's Hospital and
the Wellcome Trust Clinical Research Facility (Manches-
ter). A phased array SENSE head coil will be used to facil-
itate the production of high quality MR images with high
signal-to-noise ratio (SNR).
The total scanning time is approximated at 30 minutes
and the protocol sequence is detailed in Table 2. Sequenc-
ing is prioritized in the order listed and will depend on
how long each infant will remain still in the scanner. Data
acquisition is not expected to exceed 40 minutes.BMC Pediatrics 2008, 8:26 http://www.biomedcentral.com/1471-2431/8/26
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MRI examination will be performed at term equivalence
in infants for whom separate informed parental consent
will be obtained. No sedation will be used, as infants will
be imaged during natural sleep after having been fed.
Careful infant positioning by the radiographer will ensure
their comfort while being scanned. Patient comfort during
an MRI examination is vital for high image quality, espe-
cially when scanning neonates. Supervision will be pro-
vided for the length of the MRI scan. Ear protection
equipment for this study will comprise of pneumatic
headphones and ear plugs using President dental
putty[40] to decrease acoustic noise and to ensure infants
remain still during and in between the scans. This will
help prevent any image degradation from motion arte-
facts. Additional scanner-inbuilt acoustic noise reduction
techniques will be employed such as SOFTONE. This will
be especially important as some of the advanced MRI
methods (diffusion, angiography) can be noisy and may
wake infants up[41].
Clinical reports of the MRI scan will be sent to the named
clinician and parents will be informed of the outcome of
the scans. Image interpretation will be performed by Con-
sultant Radiologists based at Liverpool and Manchester
respectively who will have specialist pediatric MR train-
ing.
Anonymised images will be safely archived using 5.2 MB
Magneto-Optical-Discs (SONY) that will be purchased
specifically for this study. This will enable us to retrieve
those images for future reference for a larger scale study.
Image Analysis
Image analysis will be performed using specialised medi-
cal imaging software for structure-specific brain volume
measurements (Easymeasure) and software for vessel
analysis measurement (ImageJ) provided by the Magnetic
Resonance Imaging and Analysis Research Center (MARI-
ARC) and the School of Health Sciences of the University
of Liverpool.
Table 2: Sequence Protocol for TIPIT
Sequence Scan Parameters Target area
1. Midline sagittal T1 weighted Turbo Spin Echo 
(TSE)
TR = 337 ms, TE = 18 ms Slice thickness = 3 
mm, 0.3 mm gap Scan Duration = 2 minutes
Anatomical alignment and measurement of 
pituitary height
2. Coronal heavily T2 weighted TSE (whole 
brain)
TR = 5750 ms, TE = 150 ms Slice thickness = 
1.5 mm, contiguous Scan Duration = 5 minutes
Measurement of whole brain volume 
(cerebrum/cerebellum) and measurement of 
specific brain structures using stereology:
• caudate
• hippocampus
• thalamus
• prefrontal cortex
• inferior frontal gyrus
• temporal lobe
3. MR Angiography TR = 25 ms, TE = 6.9 ms Slice thickness = 0.6 
mm, 3D Time of Flight (TOF) Multiple 
Overlapping Thin Slab Acquisition (MOTSA) 
with a SENSE factor of 2.00. Isotropic 
resolution = 0.6 × 06 × 06 mm3 Scan Duration 
= 6 minutes
Blood vessel diameter, tortuosity, and density
4. Diffusion tensor imaging 2D single shot spin-echo Echo-Planar Imaging 
(SE-EPI) with SENSE factor of 2.5. 24 
contiguous axial slices of 3 mm thickness with 
in-plane isotropic resolution of 2 mm. TR/TE = 
3350/74 ms. 32 gradient directions with a b-
factor of 700 s/mm2. 2 averages. Scan Duration 
= 3 minutes 47 s.
Measurement of degree of mean diffusivity and 
fractional anisotrophy (as markers of water 
content and myelination) in
• posterior limb of internal capsule
• centrum semiovale
• anterior and posterior corpus callosum
• frontal white matter
• occipital white matter
5. Axial T2-weighted TSE TR = 3023 ms, TE = 150 ms. Axial slices of 3 
mm thickness with an in-plane isotropic 
resolution of 0.7 mm Scan Duration = 3 
minutes
In same slice location as DTI to aid region 
drawingBMC Pediatrics 2008, 8:26 http://www.biomedcentral.com/1471-2431/8/26
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Brain structure volumes will be estimated using an estab-
lished, and mathematically unbiased, stereological tech-
nique which employs the Cavalieri methods in
conjunction with point counting [42-44]. Efficient sam-
pling strategies for estimating the volumes of the struc-
tures listed in Table 2 have already been developed and
employed in numerous clinical studies[43,45-50].
DTI analysis will use DTIstudio to produce maps of mean
diffusivity and fractional anisotropy[38,39]. Regions of
interest in the structures listed in Table 2 will be drawn by
hand and the mean values recorded. In addition, fibre
tracts originating from these regions of interest will be
computed, thresholded at fractional anisotropy > 0.15.
The number and mean length of fibres will be recorded
and also the mean fractional anisotropy and mean diffu-
sivity in the tracked pathways. Further analysis will con-
sider the use of voxel-based morphometry to identify
regional group differences in fractional anisotropy and
mean diffusivity without a priori information[51]. Two
identical phantoms containing n-tridecane will be
scanned regularly on both the Manchester and Alder Hey
scanners to monitor the accuracy of the mean diffusivity
measurements[52].
Vessel diameter will be quantified using ImageJ software
and the Full-Width-at-Half-Maximum (FWHM) criterion,
as suggested by previous studies[53]. The diameters of the
proximal branches of the MCA (M1 segment) and PCA
(P1 segment) for both the left and the right side will be
measured in the transverse plane of the MIP image.
Tortuosity will be quantified using the distance factor
(DF) defined by the following ratio[54]:
Analysis will be performed by manually tracing along ves-
sels using the segmented line function of the medical
image analysis software ImageJ. A standardised anatomi-
cal length of 3 cm starting from the origin of the vessels at
the ICA (for the ACA and MCA) or at the basilar artery (for
the PCA) will be used.
Vessel density will be qualitatively assessed on the maxi-
mum intensity projection images (MIPs) on all three
orthogonal planes (axial, sagittal and coronal) and classi-
fied in five different categories, ranging from 1 (no vessel
visible) to 5 (very dense vasculature)[55].
Data Management
Data will be collected on case report forms (CRF) and
then entered on to a MACRO database. Data will be
entered blind to treatment allocation on to the password-
protected database. Access to the database will be
restricted to the investigators. All CRF hard copies will be
stored in a locked filing cabinet within the recruiting cen-
tres.
Statistical Analysis
Sample Size Calculation
The power calculation for the sample size of the study was
based on a sample size of 64 in each group which will
have 80% power to detect a difference between the means
of the thyroxine and placebo groups of 0.67 mm (0.5*SD)
for the outcome subarachnoid space at 36 weeks'
CGA[37]. This assumes that the common standard devia-
tion is 1.3 mm and analysis is based on using a two group
t-test with a 0.05 two-sided significance level. The value
for the SD is taken from Armstrong et al[56] who report
subarachnoid space as an indirect method of brain growth
in preterm infants.
Data Analyses
Primary analysis of the data will be by intention to treat.
Differences between TIPIT participants consenting to the
MRI scan and those not consenting will be investigated.
A supplementary analysis will be per protocol for the
TIPIT study. This will allow us to assess how thyroid hor-
mone status is associated with brain development.
The volumes of key brain structures, whole brain volume,
extent of myelination of cerebral white matter and white
matter integrity and brain vessel morphology will be cal-
culated for each baby and difference between the two
intervention groups will be compared between the two
groups using a two group t-test. The difference in means
will be presented with a 95% confidence interval. Multi-
ple regression will be used to adjust for baseline imbal-
ance between the groups and for potential prognostic
factors which will be identified prior to the analysis.
Ethical and Regulatory Issues
Patient Consent and Data Monitoring Committee
Parents/guardian will be given full verbal and written
information regarding the trial before written consent is
obtained. An independent Data Monitoring and Ethics
Committee (DMEC) will be formed. During the period of
recruitment, interim summaries of results will be sup-
plied, in strictest confidence, to the DMEC by the trial stat-
istician (see main TIPIT protocol[37] for details).
Regulatory bodies
EUDRACT number : 2005-003-09939
MHRA approval was granted 15th June 2007
DF=
Standardised vessel length between defined end points
Len ngth of the straight line with same end pointsBMC Pediatrics 2008, 8:26 http://www.biomedcentral.com/1471-2431/8/26
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North West Research Ethics Committee gave a favourable
ethical opinion to the study on 12th June 2007.
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